You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Luspatercept intolerant

Showing 1 - 25 of 539
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS, Del(5Q), Anemia Trial in Italy (Luspatercept Injection [Reblozyl])

Recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Luspatercept Injection [Reblozyl]
  • Alessandria, Italy
  • +22 more
Jun 20, 2023

MDS Trial in Beijing (Roxadustat, Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
    Peking union medical college hospital
Aug 17, 2023

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

MDS Trial in Worldwide (Luspatercept, Placebo)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Stanford, California
  • +73 more
Nov 19, 2021

Low Risk MDS Trial (R906289 Monosodium (R289 Na))

Not yet recruiting
  • Low Risk Myelodysplastic Syndromes
  • R906289 Monosodium (R289 Na)
  • (no location specified)
Jul 22, 2022

Luspatercept in Korean Myelodysplastic Syndrome or ß-thalassemia

Not yet recruiting
  • Myelodysplastic Syndrome
  • Beta Thalassemia
  • Seoul, Korea, Republic of
    Bristol-Myers Squibb YH
Oct 3, 2023

MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Feb 16, 2023

MDS (MDS), Beta-thalassemia, Myeloproliferative Tumor(MPN)-Associated Myelofibrosis Trial in Worldwide (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes (MDS)
  • +2 more
  • Los Angeles, California
  • +203 more
Jan 30, 2023

MDS Trial in Houston (Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2023

Myelodysplastic/Myeloproliferative Tumor With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Tumor,

Recruiting
  • Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 6, 2023

MDS Trial in Worldwide (Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Los Alamitos, California
  • +53 more
Sep 13, 2023

Anemia Trial (Luspatercept)

Not yet recruiting
  • Anemia
  • Luspatercept
  • (no location specified)
May 26, 2023

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Epoetin Alfa
  • Concord, California
  • +100 more
Jul 20, 2023

Thalassemia Trial in Worldwide (Luspatercept, Placebo, Best Supportive Care (BSC))

Active, not recruiting
Has Results
  • Thalassemia
  • Los Angeles, California
  • +16 more
Aug 16, 2022

Anemia Trial in Worldwide (biological, drug, other)

Recruiting
  • Anemia
  • Luspatercept
  • +2 more
  • Halifax, Nova Scotia, Canada
  • +11 more
Jan 3, 2023

Beta-thalassemia Trial in Nanning (Luspatercept, Placebo)

Recruiting
  • Beta-thalassemia
  • Nanning, China
  • +1 more
Jan 13, 2023

Thalassemia Major, Transfusion-dependent Anemia Trial in Guangzhou (Luspatercept Injectable Product)

Recruiting
  • Thalassemia Major
  • Transfusion-dependent Anemia
  • Luspatercept Injectable Product
  • Guangzhou, Guangdong, China
    The second affiliated hospital of Sun Yat-sen University
Jul 15, 2022

MDS Trial in United States (Lenalidomide, Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Miami, Florida
  • +5 more
Sep 28, 2022

MDS, MDS Trial in France (Luspatercept Injection [Reblozyl], Eprex)

Recruiting
  • MDS
  • Myelodysplastic Syndromes
  • Luspatercept Injection [Reblozyl]
  • Eprex
  • Amiens, France
  • +30 more
May 19, 2022

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Hypercholesterolemia Trial in Japan (K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily))

Recruiting
  • Hypercholesterolemia
  • K-877 0.2 mg/day (once daily)
  • +2 more
  • Aichi, Japan
  • +14 more
Jun 20, 2023

MDS Trial in China, Japan (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
  • +33 more
Aug 16, 2022

Primary Myelofibrosis, Anemia Trial in Worldwide (Luspatercept)

Completed
  • Primary Myelofibrosis
  • Anemia
  • Phoenix, Arizona
  • +24 more
Aug 17, 2022

MDS Trial in Germany (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Hamburg, Germany
  • +4 more
Dec 20, 2021